Fundraising Fox
Edwards Lifesciences
NYSE: EWIrvine, US · Delaware corporation · 3 known investors
Find your way into Edwards Lifesciences
Sign up to see every warm intro you have to Edwards Lifesciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Edwards Lifesciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Edwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$307.2M disclosed across 2 rounds · 2017–2018
▶$34.9MraisedJun 2018 · 25 investors · BiotechnologyRule 506(b)
- William J. LinkDirector
- Kieran T. GallahueDirector
- Jean-Luc LemercierExecutive Officer
- Leslie S. HeiszDirector
- Donald E. Bobo, Jr.Executive Officer
- Nicholas J. ValerianiDirector
- Steven R. LorangerDirector
- Wesley W. von SchackDirector
- Martha H. MarshDirector
- Catherine M. SzymanExecutive Officer
- Larry L. WoodExecutive Officer
- Michael A. MussallemExecutive Officer, Director
- Huimin WangExecutive Officer
- Scott B. UllemExecutive Officer
- Offering amount
- $34.9M
- Amount sold
- $34.9M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$272.4MraisedFeb 2017 · 25 investors · BiotechnologyRule 506(b)
- Nicholas J. ValerianiDirector
- William J. LinkDirector
- Steven R. LorangerDirector
- Donald E. Bobo, Jr.Executive Officer
- Wesley W. von SchackDirector
- Scott B. UllemExecutive Officer
- Larry L. WoodExecutive Officer
- Leslie S. HeiszDirector
- Huimin WangExecutive Officer
- Catherine M. SzymanExecutive Officer
- John T. CardisDirector
- Bernard J. ZovighianExecutive Officer
- Michael A. MussallemExecutive Officer, Director
- Patrick VerguetExecutive Officer
- Kieran GallahueDirector
- Martha H. MarshDirector
- Offering amount
- $272.4M
- Amount sold
- $272.4M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Edwards Lifesciences mafia →13 people who came through Edwards Lifesciences went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Edwards Lifesciences.
Acquisitions · 5
Early investors' stakes continue via these dealsCardiAQ Valve Technologies developed a transcatheter mitral valve replacement system enabling minimally invasive treatment of mitral valve disease without open-heart surgery.
CardiAQ Valve Technologies developed a transcatheter mitral valve replacement system that could be implanted in a beating heart without open-heart surgery, using an anchoring mechanism engaging native valve anatomy.
Embrella Cardiovascular developed a cerebral embolic protection device inserted via the brachial or radial artery to deflect embolic debris during transcatheter heart valve procedures, reducing stroke risk. The company was founded in 2007 and based in Wayne/Malvern, PA.
Embrella Cardiovascular was a Pennsylvania-based medical device startup that developed the Embrella Embolic Deflector System, a disposable aortic device to deflect embolic material and reduce stroke risk during transcatheter heart valve replacement procedures.
University of Maryland spin-out commercializing minimally invasive image-guided surgical tool for beating heart mitral valve repair (acquired by Edwards Lifesciences in December 2017).
In the news
Frequently asked questions
- What does Edwards Lifesciences do?
- Edwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.
- Who are Edwards Lifesciences's investors?
- Edwards Lifesciences's investors include ALIVE Israel HealthTech Fund, Peregrine Ventures, Versant Venture AIV Holdings.
- How much funding has Edwards Lifesciences raised?
- Edwards Lifesciences has disclosed $307.2M raised across 2 rounds.
- Where is Edwards Lifesciences headquartered?
- Edwards Lifesciences is headquartered in Irvine, US.